CENTER TO BOOST BIOMANUFACTURING IN ENGLAND
Momentum is growing at the UK's new National Biomanufacturing Centre (NBC) as Eden Biodesign inked a second contract at the center set up to establish Northwest England as one of the top biomanufacturing hubs in Europe.
Under the new contract, Eden will develop and manufacture monoclonal antibodies against a novel cancer antigen, to be used in investigational cancer-killing drugs being developed by the University of Liverpool.
The UK is now second only to the U.S. in terms of its biopharmaceuticals development pipeline; however, the country's industry still lags a long way behind the U.S., and the UK government has been making a concerted effort to close this gap.
The NBC, which officially opens later this year, is a £34.3 million (⁈49.8
million) government-funded initiative led by the Northwest Regional Development
Agency to assist UK academia in developing and commercializing their biopharma
discoveries.